Cardiovascular Risk with Elevated Cardiac Troponin Levels After Stroke or TIA

Risk is elevated, but the clinical utility of this blood biomarker to guide management is still unclear.

After minor stroke or transient ischemic attack (TIA), secondary prevention efforts typically focus on preventing recurrent cerebrovascular events. However, the risk for coronary events is also elevated. Whether blood biomarkers in conjunction with risk stratification scores can help identify patients who would benefit from more extensive cardiac workups and targeted interventions is unclear. In an ancillary study of participants in the partially industry-funded INSPiRE-TMS trial, investigators categorized 889 patients with minor stroke or TIA by high-sensitivity cardiac troponin T (hs-cTnT) level and by ABCD² (age, blood pressure, clinical features, duration, diabetes) score.

During an average of 3.2 years of follow-up, 153 patients had inc…

Reviewing Author

Anthony S. Kim, MD

Disclosures

Grant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences

Anthony S. Kim, MD

Disclosures

Grant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences

Cardiovascular Risk with Elevated Cardiac Troponin Levels After Stroke or TIA

Topics

Reviewing Author